257 related articles for article (PubMed ID: 21548475)
1. Sorafenib for HCC: a pragmatic perspective.
Razumilava N; Gores GJ
Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
[No Abstract] [Full Text] [Related]
2. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Burak KW
Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
[No Abstract] [Full Text] [Related]
3. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
4. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R; Byrne MT; Tan A; Aucejo F
Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and sorafenib.
Spinzi G; Terreni N
Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
[No Abstract] [Full Text] [Related]
7. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Zhu AX; Clark JW
Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
[No Abstract] [Full Text] [Related]
8. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
Abou-Alfa GK
Oncologist; 2009 Jan; 14(1):92-4. PubMed ID: 19144679
[No Abstract] [Full Text] [Related]
9. Sorafenib for liver cancer: the horizon broadens.
Johnson P; Billingham L
Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
[No Abstract] [Full Text] [Related]
10. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Rowe IA
Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
[No Abstract] [Full Text] [Related]
11. Selection of patients with hepatocellular carcinoma for sorafenib.
Abou-Alfa GK
J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
[TBL] [Abstract][Full Text] [Related]
12. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Zhu AX
Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
[No Abstract] [Full Text] [Related]
14. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Greten TF; Manns MP; Malek N
Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
Pazo Cid RA; Lao J; Lanzuela M
JAMA; 2011 Feb; 305(8):781; author reply 781. PubMed ID: 21343576
[No Abstract] [Full Text] [Related]
16. Hepatocellular carcinoma: The beginning of a long journey.
Cascinu S
Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
[No Abstract] [Full Text] [Related]
17. Sorafenib, a systemic therapy for hepatocellular carcinoma.
Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
[TBL] [Abstract][Full Text] [Related]
18. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
19. Developing better treatments in hepatocellular carcinoma.
Duffy A; Greten T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
[TBL] [Abstract][Full Text] [Related]
20. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.
Llovet JM; Bruix J
J Clin Oncol; 2009 Feb; 27(6):833-5. PubMed ID: 19139428
[No Abstract] [Full Text] [Related]
[Next] [New Search]